{"id":"ab11a84e-4379-5dfb-968a-8c65c0147150","stable_key":"ec987f3e-0b3c-55cc-b304-c703a738e35d:egcg-bortezomib-proteasome","predicate":"attenuates","statement":"Direct EGCG–bortezomib reaction prevented proteasome inhibition and downstream stress/death responses; tested nonboronic inhibitors did not show the same antagonism.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"ec8f6d9d-3d20-5145-a60e-a80f170e72a5","mechanism_event_label":"The proposed interference starts with drug chemistry.","subject":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"object":{"id":"e60a0036-07b4-5513-a235-fce3982d58d2","slug":"bortezomib-proteasome-inhibition","display_name":"Bortezomib-mediated proteasome inhibition","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ec8f6d9d-3d20-5145-a60e-a80f170e72a5","stable_key":"ec987f3e-0b3c-55cc-b304-c703a738e35d:egcg-bortezomib-proteasome-event","event_type":"observed_relationship","label":"The proposed interference starts with drug chemistry.","description":"Direct EGCG–bortezomib reaction prevented proteasome inhibition and downstream stress/death responses; tested nonboronic inhibitors did not show the same antagonism.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"e60a0036-07b4-5513-a235-fce3982d58d2","slug":"bortezomib-proteasome-inhibition","display_name":"Bortezomib-mediated proteasome inhibition","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"7c75470d-e9e0-5a6b-b342-6a1201da6b13","slug":"bortezomib","display_name":"Bortezomib","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"17ae4bd3-4ae7-5d58-8aa6-3b13869532ef","slug":"egcg-bortezomib-adducts","display_name":"EGCG–bortezomib boronate and borate adducts","entity_type_key":"chemical_species"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"Myeloma/glioblastoma cell experiments and animal models in the 2009 Blood study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Preclinical findings; no human coadministration outcome trial. Chemical form and simultaneous concentrations matter.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"EGCG collection; comparator and shared-pathway records retain their actual intervention.","comparator":null,"unit":null,"notes":"","entity":{"slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The proposed interference starts with drug chemistry.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19190249/ · DOI 10.1182/blood-2008-07-171389","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3a4bc779-0342-5d17-927a-209803be3cf1","evidence_kind":"source_excerpt","locator":"Lines 404-410","start_line":404,"end_line":410,"excerpt":"## egcg-bortezomib-proteasome\nThe proposed interference starts with drug chemistry.\nDirect EGCG–bortezomib reaction prevented proteasome inhibition and downstream stress/death responses; tested nonboronic inhibitors did not show the same antagonism.\nModel: Myeloma/glioblastoma cell experiments and animal models in the 2009 Blood study.\nLimitations: Preclinical findings; no human coadministration outcome trial. Chemical form and simultaneous concentrations matter.\nEvidence access: primary abstract.\nGreen tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19190249/ · DOI 10.1182/blood-2008-07-171389","model_system":"Myeloma/glioblastoma cell experiments and animal models in the 2009 Blood study.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Primary-abstract paraphrase; no full-text methods verification claimed.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"1f6d09e8-3aae-5c41-9ea7-15d0d1cab72d","stable_key":"import-ec987f3e-0b3c-55cc-b304-c703a738e35d","title":"EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b101c8d4d96ee03ff97eb1922c7bb0f96943295af473fdc3ef98b0dbd62fe8c7","revision_id":"e19bc5b2-ee3c-5f67-b5c5-9dc3b7d5f850","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}